MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Pharmacol Res
; 161: 105157, 2020 11.
Article
in En
| MEDLINE
| ID: mdl-32814169
Key words
A23187 (PubChem CID: 40486); AICAR (PubChem CID: 46780289); BODIPY (PubChem: CID: 25058173); Cisplatin (PubChem CID: 441203); Erastin (PubChem CID: 11214940); Ferrostatin 1 (PubChem CID: 4068248); MAP30; NaCl (PubChem CID: 5234); PVDF (PubChem CID: 3082294); Phenylmethylsulfonyl fluoride (PMSF) (PubChem CID: 4784); Propidium iodide (PI) (PubChem CID: 104981); STO-609 (PubChem CID: 3467590); Tris-HCl (PubChem CID: 93573); bitter melon; chemoresistance; ferroptosis; metabolism; ovarian cancer
Full text:
1
Database:
MEDLINE
Traditional Medicines:
Medicinas_tradicionales_de_asia
/
Medicina_china
Main subject:
Ovarian Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Cisplatin
/
Momordica charantia
/
Energy Metabolism
/
Ribosome Inactivating Proteins, Type 2
/
Ferroptosis
/
Antineoplastic Agents, Phytogenic
Type of study:
Prognostic_studies
Language:
En
Journal:
Pharmacol Res
Year:
2020
Type:
Article